Message from University of Colorado Cancer Center Director Richard Schulick MD, MBA

Together we are people united in a single goal: To Discover, Develop and Deliver treatments that save, extend, and enrich lives.

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer

Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months.

Without “yoga and chardonnay” leukemia stem cells are stressed to death

CU Cancer Center researchers nix stress-relief pathway to kill leukemia stem cells while leaving healthy blood stem cells unharmed

These breast cancer patients are still INVISIBLE

In breast cancer, the sickest patients receive the least research funding. Christine Howard is changing that.

Latest News from the University of Colorado Cancer Center

@CUCancerCenter on Twitter